18,845 Shares in Revolution Medicines, Inc. $RVMD Bought by Landscape Capital Management L.L.C.

Landscape Capital Management L.L.C. acquired a new stake in Revolution Medicines, Inc. (NASDAQ:RVMD) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 18,845 shares of the company’s stock, valued at approximately $1,501,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Global Retirement Partners LLC increased its holdings in Revolution Medicines by 1,002.8% in the fourth quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock valued at $32,000 after buying an additional 361 shares in the last quarter. Indiana Trust & Investment Management Co purchased a new position in Revolution Medicines in the fourth quarter valued at $32,000. Torren Management LLC purchased a new position in Revolution Medicines in the fourth quarter valued at $33,000. Arax Advisory Partners purchased a new position in Revolution Medicines in the fourth quarter valued at $38,000. Finally, Darwin Wealth Management LLC purchased a new position in Revolution Medicines in the fourth quarter valued at $40,000. Hedge funds and other institutional investors own 94.34% of the company’s stock.

Insider Activity

In other news, insider Mark A. Goldsmith sold 120,000 shares of the company’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $150.09, for a total transaction of $18,010,800.00. Following the completion of the sale, the insider owned 276,698 shares of the company’s stock, valued at $41,529,602.82. This represents a 30.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 7.60% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. UBS Group initiated coverage on shares of Revolution Medicines in a report on Friday, February 27th. They issued a “buy” rating for the company. Guggenheim boosted their price target on shares of Revolution Medicines to $205.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Oppenheimer boosted their price target on shares of Revolution Medicines from $165.00 to $195.00 and gave the stock an “outperform” rating in a report on Monday, June 1st. Benchmark reissued an “overweight” rating on shares of Revolution Medicines in a report on Tuesday, February 17th. Finally, Evercore reissued an “outperform” rating on shares of Revolution Medicines in a report on Tuesday, April 14th. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Revolution Medicines has a consensus rating of “Buy” and a consensus price target of $123.72.

Revolution Medicines Price Performance

Revolution Medicines stock opened at $160.06 on Tuesday. Revolution Medicines, Inc. has a 52-week low of $34.00 and a 52-week high of $166.50. The firm has a market capitalization of $34.03 billion, a price-to-earnings ratio of -22.64 and a beta of 1.40. The company has a fifty day simple moving average of $141.98 and a 200-day simple moving average of $111.27. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.19.

Revolution Medicines (NASDAQ:RVMD) last released its earnings results on Wednesday, May 6th. The company reported ($2.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.83) by ($0.46). During the same period last year, the firm earned ($1.13) EPS. On average, equities analysts anticipate that Revolution Medicines, Inc. will post -7.94 EPS for the current fiscal year.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.